Know Cancer

or
forgot password

Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy


N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer, Colorectal Cancer, Head and Neck Cancer

Thank you

Trial Information

Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy


This study is to establish a pilot pharmacogenomic program in identifying genetic variation
to predict the safety, toxicity and/or efficacy of drugs. DNA will be extracted from
patients' peripheral blood to study SNPs in DPD, TS, MTHFR, UGT1A1, CYP3A4, CYP3A5, GSTM1,
GSTT1, GSTP1, HO-1, ERCC1, XPD, XRCC1 and EGFR genes. The results of genetic study will be
compared to treatment efficacy and toxicity. The ultimate goal is to use genotype profiles
to provide individualized cancer treatment to improve outcome and decrease toxicity.


Inclusion Criteria:



- Lung, Colorectal and Head and Neck Cancer Patients that have received or plan to
receive chemotherapy as part of their treatment

Exclusion Criteria:

- Colorectal cancer patients that have never received or will not receive chemotherapy
as part of their therapy

- Head and Neck cancer patients that have never received or will not receive
chemotherapy as part of their treatment

- Patients with cancer types other than colorectal or head and neck

- Unable to give informed consent

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Yu-Jui Yvonne Wan, Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Kansas

Authority:

United States: Institutional Review Board

Study ID:

10270

NCT ID:

NCT00442520

Start Date:

February 2006

Completion Date:

September 2008

Related Keywords:

  • Lung Cancer
  • Colorectal Cancer
  • Head and Neck Cancer
  • Colorectal Neoplasms
  • Head and Neck Neoplasms
  • Lung Neoplasms

Name

Location

University of Kansas Medical CenterKansas City, Kansas  66160-7353